Ro Launches Foundayo, Second Oral GLP-1 Option
Ro has recently expanded its obesity treatment portfolio by adding Foundayo, an oral GLP-1 receptor agonist. This new medication…
-
-
Amazon Pharmacy Expands Access to Oral Weight Management Treatments
Amazon Pharmacy is now delivering the recently authorized medication Foundayo to patients nationwide. This GLP-1 therapy is intended for…
-
Eli Lilly Faces Policy Pressure as FDA Approval of Oral GLP-1 Drug Foundayo Reshapes the 2026 Outlook
The year 2026 brings a mix of success and stress for major drug makers. While sales numbers look strong,…
-
New Weight-Loss Pill Foundayo vs Wegovy and Zepbound: What Sets It Apart
The Food and Drug Administration approved Foundayo on April 1, 2026. Reviewers used a special priority program to finish…
-
FDA Approves Foundayo as Eli Lilly Expands Oral Weight Loss Portfolio
The Federal Food and Drug Administration approved Foundayo for chronic weight management on April 1, 2026. This oral medication…
-
Genetic and Ancestral Differences in GLP-1 Drug Response Identified in Large Biobank Study
A major new study shows that a person’s background can change how they react to popular weight-loss drugs. Researchers…
-
Hims & Hers Partners with Novo Nordisk to Expand Access to FDA-Approved GLP-1 Medications
Hims and Hers Health recently launched a massive expansion of its telehealth services. The platform now offers a wide…
-
Do GLP-1 Medications Such as Ozempic Contribute to Increased Longevity?
GLP-1 drugs have changed how doctors treat type 2 diabetes and obesity. Medicines like semaglutide do more than just…
-
GLP-1 Receptor Agonists for Metabolic Management in Cushing Syndrome
Cushing syndrome presents profound metabolic challenges for clinical endocrinologists. Prolonged cortisol exposure drives severe central obesity and systemic inflammation….
-
Next-Generation GLP-1 Therapies Transform Obesity Treatment
An oral formulation of semaglutide was recently approved by the Food and Drug Administration. This pill is already part…
